Member Info for Notposting

There is nothing to say it is working definitively. At this stage, in preliminary, it is only believed to be working based on standard testing, which is not conclusive. This is not uncommon at this stage in part. Until full data is available, there is simply insufficient information to draw firm conclusions.

He hasn’t “played a blinder.” Risk has not been managed effectively, which has led to weak funding options. No CEO should rely on workarounds as the basis for a company’s future. The recent raises reflect this, as one-to-one warrants in effect cut the placing price by 50%. Any participant is incentivised to dispose of shares while keeping the warrants risk-free, creating a rinse-and-repeat cycle that comes at the expense of shareholders. Hence I suspect the misleading hype posts from said individuals who are trying desperately to support the share price to sell or maximise the profit from the exercise of their warrants.

That said, costs have been reduced, progress has been made, and there is some momentum. However, the peak would have been the right moment to secure a longer-term runway, without warrants and any likely upfront costs required to advance Estonia, if that is to proceed.

It’s worth noting that there are only around six early-stage biopharmaceutical companies on AIM above £100m, and just two on the Main Market.

Hemogenyx is a long way from those levels for multiple reasons. It will not grow meaningfully until there is sustained positive progress, another product moves forward, or credible interest is shown from a significant partner, especially given the company’s history. Hopefully, at some point, the larger investors or biopharmaceutical companies with real knowledge may show interest. That is when it matters, not when a few hyping investors on here claim they have cornered the market, suddenly become “scientists” because of AI, and base their arguments on assumptions rather than facts.

The share price speaks for itself, and there are far larger and more experienced players countering these claims by the market interest shown at the higher levels. This is not negativity, it is realism. What I am highlighting is the gap between facts and the narrative being sold, often to onlookers while some are likely cashing out, or at best, sitting on reduced risk having already sold part of their holding.

If Estonia was such a goldmine... the market would speak and support that narrative. It isn’t.

He hasn’t entered into anything “commercial” yet. This is a non-binding agreement with undisclosed terms, revenue potential, or hurdles. By his own admission, he doesn’t expect it to be substantial.

Any acceptance of patients also comes with strict conditions, so no, this isn’t about to become a goldmine.

If the FDA halts or delays any part of the next phases, that “commercialisation” goes nowhere and likely halts alongside it.

Paediatrics adds scrutiny and risk, not less, and rightly so. The same applies to increased dosing.

It also helps to remember your repeated comments about people being “cured” or about commercialisation being meaningful, which are speculative at best. Likewise, comments around contractors are misleading. They are effectively employed by Hemogenyx, not chosen independently for scientific reasons at this stage.

The Estonian government has yet to agree as well.

At the moment, there is still a lot of talk and very little substance, which seems to be the theme of your posts.

So many misleading statements.

“its worth taking a step back and being impartial....”

Erm. Yes. Indeed. Please do.

And you also don’t know if all three are still alive. Nor is it a “cure” as such although positive thus far, and Estonia isn’t ever going to fully fund trials, if they even go ahead. It’s going to need funding irrespective.

The fact is, you got lucky. Pretending otherwise puts you in the same category as the ramping ‘LTHs’ who are selling into their own hype.

With respect, Made and Cellin are contractors. They don’t actually choose which company to get involved or ratify the science by working with someone. It is who pays them that forms that decision.

LTH? More like lets the de ramp/ hype roll according to where his position sits.

I have. Behave.

Haywain, it doesn’t, but you shouldn’t be attacking someone for calling out damaging behaviour. That’s wrong. I have nothing against you, as I don’t know you, but you shouldn’t have made that comment. I haven’t talked the price down at all today. I’m indifferent, but it’s clear as day what the motive was behind Let it Roll’s posts. I also hope the science proves successful.

To add, no chart has ever indicated a drop to £8.50, nor will the interims have any significant negative or positive impact, contrary to what the so-called LTH suggested when his first attempt to talk it down failed.

Does ChatGPT not provide accurate responses when replying normally? You seem confused. It wasn’t me talking the price down after their trade - it was your so-called LTH, Let it Roll.

You’re not here for the science; like everyone else, you’re here to make money. Drop the moral narrative and be more mindful of your responses when they’re based on incorrect assumptions.

Let-It-Roll Premium Member

Posted in: HEMO

Posts: 786

Price: 1,175.00

No Opinion

RE: FOMO for MondayToday 12:21

Monday RNS will likely be the Interims, so up to June. Probably be used as an excuse to play this down further.

Even though the future is bright!

Let-It-Roll Premium Member

Posted in: HEMO

Posts: 786

Price: 1,140.00

No Opinion

RE: Down 7%Today 09:37

Regrettably, and I really hope I'm wrong, but this is being driven down. I had thought it would settle in a range around £13. But i think it might now end up around £8.50 looking at the current chart which is crazy.

Ahh, Let It Roll. I assume the misleading ramping will now resume, till you have sold again? When, I assume your de ramping will resume? Hopefully most have marked your card today.

Let it Roll - the audacity. Just yesterday it was posting misleading hype about £34 a share, and today it’s talking it down.

To those following blindly: mark the cards.

The same Individuals selling as you buy.

I don’t expect anything unexpected in the results, positive or negative, so they shouldn’t have any real impact on the share price. What tends to create a negative effect is the kind of misleading nonsense posted by some here, especially the ilks of Let it Roll & CheckRicky who would have been selling whilst posting the opposite.

“Long term holders” after ramping and exiting.

Class.

There is no such potential. It’s a false narrative by you.

Is there anything you don’t know? You seem to know things even those directly involved don’t, like Mystic Meg. There are over 8 billion people in the world, so if you somehow know me, you should probably play the lottery, as I’ve never (thankfully) spoken to you before this exchange.

I don’t need to. You don’t know the committee, nor what has been done. The share price will support the correct narrative in the short term. Try to keep your emotions under control. It is Vlad, not Vladik; he isn’t a friend of yours. I understand you want to appear closer to him than you are, and more important and knowledgeable than you’ve demonstrated. Whatever makes you feel better. Have a good day.